Welcome to this comprehensive guide on Vascular Anomalies: Classification, Diagnosis, and Management, designed to help students like you understand these complex conditions. Vascular anomalies are a newly evolved field that incorporates several surgical and medical specialties, and a standardized terminology is crucial for proper understanding and treatment. These disorders usually involve the skin, making initial consultation often with a plastic surgeon or pediatric dermatologist.
This article will clarify the distinctions between vascular tumors and malformations, delve into their specific types, and outline the approaches to their diagnosis and management. It aims to provide a clear summary of the topic, making it an excellent resource for your studies or exam preparation.
Vascular Anomalies: Classification and Core Differences
To truly understand vascular anomalies, it's essential to grasp the fundamental distinction between vascular tumors and vascular malformations. This biological classification system, introduced in 1982 by Mulliken and Glowacki, cleared up much terminological confusion. It replaced older, imprecise terms that often led to misdiagnosis and inappropriate treatment.
Tumors vs. Malformations
Vascular anomalies are broadly divided into two major categories: tumors and malformations. This distinction is based on their cellular features and biological behavior. Vascular tumors are characterized by increased endothelial turnover—meaning the cells lining the blood vessels are actively proliferating. They are neoplasms, or new growths, arising from upregulated cellular growth. Vascular malformations, on the other hand, result from abnormal development of vascular elements during embryogenesis. Their endothelial lining is more quiescent, meaning the cells are not rapidly multiplying. They are fundamentally structural disorders.
Misleading Terminology in Vascular Anomalies
Historically, many vascular lesions were mislabeled, leading to significant confusion. Here are some key points about incorrect terminology: * "Congenital" and "Acquired": These terms should be used cautiously. "Congenital" should be restricted to lesions fully expressed at birth. Vascular malformations are present at a cellular level at birth but may not manifest until later in life. "Acquired," often used for lesions appearing after one year, is inappropriate for anomalies present but not clinically apparent at birth. * "Hemangioma": This term was often applied generically and indiscriminately. There is no such entity as "cavernous hemangioma." A lesion is either a deep infantile hemangioma or a venous malformation. * Other Incorrect Terms:Table of Incorrect Terminology:| Biologic Name | Incorrect Term Commonly Used ||---------------------------|------------------------------------------|| Infantile Hemangioma | "Capillary hemangioma," "Cavernous hemangioma," "Strawberry hemangioma" || Capillary Malformation | "Port-wine stain," "Capillary hemangioma" || Hemangioendothelioma | "Capillary hemangioma" || Lymphatic Malformation | "Cystic hygroma," "Lymphangioma" || Venous Malformation | "Cavernous hemangioma" || Arteriovenous Malformation| "Arteriovenous hemangioma" |
Vascular Tumors: Types and Characteristics
Vascular tumors are characterized by active cellular proliferation. They include various types, each with unique features and management strategies.
Infantile Hemangioma (IH): An OverviewInfantile Hemangioma (IH) is the most common tumor of infancy, affecting approximately 4-5% of Caucasian infants, more frequently in premature children and females (4:1 ratio). It's a benign endothelial tumor with a unique biological behavior: it grows rapidly, slowly regresses, and never recurs. This behavior led to its classification by the International Society for Vascular Anomalies in 1996. * Pathogenesis: IH arises from vasculogenesis (formation of blood vessels from progenitor cells) rather than angiogenesis. Hemangioma-derived stem cells (HemSCs) are believed to be precursor cells, expressing CD90 and differentiating into endothelium. Hypoxia, increased circulating endothelial progenitor cells, and defective NFAT activity contributing to increased VEGF-A are thought to stimulate rapid growth. Involution involves increased apoptosis and replacement by fibrofatty tissue, possibly influenced by decreasing maternal estrogens or increased angiogenesis inhibitors. * Clinical Features and Natural History: IH typically appears around 2 weeks of age, with 30-50% noted at birth as a stain or pale spot. It's usually single (80%) and involves the head and neck (60%), trunk (25%), or extremity (15%). Its life cycle has three phases: * Proliferating Phase (0-1 year): Rapid growth, achieving 80% of its size by 3.2 months. Superficial lesions are red; deeper ones may appear bluish. Histologically, clusters of plump endothelial cells are seen. * Involuting Phase (1-4 years): Growth plateaus after 9-12 months, then regression begins. Color fades, and the lesion flattens. Mature blood vessels form, with increased extracellular matrix and pericytes. * Involuted Phase (after 4 years): Involution ceases for most children by age 4. The IH is replaced by adipocytes and connective tissue, with thin-walled vessels remaining. Half of children may have residual telangiectasias, scarring, fibrofatty residuum, redundant skin, or destroyed anatomical structures. * Complications: While most IH are harmless, 10% cause significant deformity or complications, especially on the head or neck. * Ulceration: Occurs in at least 16% of lesions, usually around 4 months. Common in trauma-prone areas (lips, neck, anogenital). * Head and Neck Hemangiomas: Can destroy eyelids, ears, nose, or lips; cause alopecia (scalp/eyebrow); block visual axis (periorbital); or obstruct the airway (subglottic). * Multiple Hemangiomas: About 20% of infants have more than one IH. "Hemangiomatosis" designates five or more small tumors, increasing the (low) risk of internal organ involvement, most commonly the liver. * Hepatic Hemangiomas: Most common extracutaneous site. Subtypes are focal, multifocal, or diffuse. Large tumors can cause heart failure, hepatomegaly, anemia, or hypothyroidism (due to deiodinase inactivating thyroid hormone). Focal hepatic IH may be a variant of rapidly involuting congenital hemangioma (RICH). * PHACE Association: Affects 2.3% of IH patients, characterized by plaque-like facial IH with at least one of: Posterior fossa brain malformation, Hemangioma, Arterial cerebrovascular anomalies, Coarctation of the aorta and Cardiac defects, Eye/Endocrine abnormalities. An "S" is added for Sternal clefting or Supraumbilical raphe (PHACES). High risk of stroke (8%). * Reticular Hemangioma: Uncommon IH variant, often lumbosacral or lower extremity, more prone to ulceration, rarely causing cardiac overload. Associated with ventral-caudal malformations. * Diagnosis: Primarily by history and physical examination. Hand-held Doppler confirms fast-flow. Ultrasonography shows fast-flow, decreased arterial resistance, and increased venous drainage. MRI is isointense on T1, hyperintense on T2, and enhances in the proliferating phase. GLUT1 immunostaining differentiates IH from other vascular tumors and malformations. * Management: * Observation: Most small, localized, asymptomatic IH are observed. Monthly follow-up during proliferation, then annually during involution if surgery for residuals might be needed later. * Wound Care for Ulceration: Keep moist with hydrated petroleum. Anogenital IH may need petroleum gauze barrier. Clean gently with soap/water. Topical antibiotic ointment for small ulcers; damp-to-dry dressings for large/deep. Topical lidocaine for discomfort (avoid EMLA in infants <3 months due to methemoglobinemia risk). Direct pressure for bleeding. Corticosteroids can accelerate healing. * Topical Corticosteroid: Relatively ineffective for deep components. Ultrapotent agents for very superficial IH, but risk hypopigmentation, atrophy, adrenal suppression. * Intralesional Corticosteroid: For small, well-localized IHs obstructing visual axis or nasal airway, or risking damage (eyelid, lip). Triamcinolone (3 mg/kg) stabilizes growth in >95% and shrinks 75%. Risks include fat atrophy, and rarely blindness (periorbital). * Systemic Pharmacotherapy: For problematic IH >3-4 cm. * Oral Prednisolone: Used for over 40 years, safe and effective. Prednisolone 3 mg/kg/day for one month, then tapered until 10-12 months of age. Stabilizes growth in 100%, causes accelerated regression in 88%. Side effects: cushingoid appearance (20%), decreased height gain (12%, transient). * Propranolol: Effective, but safety/efficacy vs. corticosteroids not fully studied. Risks: bronchospasm, bradycardia, hypotension, hypoglycemia, seizures, hyperkalemia. May conceal heart failure symptoms. Not for patients with asthma, glucose abnormalities, congenital heart disease, or cerebrovascular malformations (PHACES). Requires close monitoring (cardiology consult, ECG, echo, glucose, electrolytes, BP, HR). Inpatient initiation for children <3 months, premature, or with airway disease. Current preference leans towards corticosteroids due to established safety profile and less intensive monitoring requirements. * Interferon: No longer recommended for children <12 months due to neurologic sequelae (spastic diplegia). * Vincristine: Second-line option if prednisolone/propranolol fail or are contraindicated. * Embolic Therapy: For large IH (e.g., multifocal hepatic lesions) causing high-output congestive heart failure. Initial control while systemic corticosteroid takes effect. Drug therapy continues until natural involution begins. * Laser Therapy: Little role for pulsed-dye laser during proliferating phase; only affects superficial portion, risks atrophy, hypopigmentation, ulceration. Indicated in involuted phase for residual telangiectasias. * Operative Management: * Proliferative Phase (infancy): Generally not recommended due to high vascularity, risk of blood loss, iatrogenic injury, and inferior outcome. Indications: pharmacotherapy failure/contraindication, well-localized tumor in favorable area, or if future resection scar would be similar. Circular excision with purse-string closure for visible circular lesions (e.g., face) to minimize scar length. * Involuting Phase (early childhood): Safer, less vascular. For significant deformity (fibrofatty tissue, excess skin, damaged structures), or if future scar length would be similar. Advantage: reconstruction before child develops memory of facial difference. * Involuted Phase (late childhood): Waiting ensures least tissue is resected for smallest scar. Weighed against psychosocial implications of prolonged deformity.
Congenital Hemangiomas (CH)Rare hemangiomas that are fully grown at birth with no postnatal growth. They are red-violaceous with coarse telangiectasias, central pallor, and a peripheral pale halo. Typically solitary, average 5 cm, common in extremities. * Rapidly Involuting Congenital Hemangioma (RICH): Involutes rapidly after birth; 50% by 7 months, fully by 14 months. Does not leave significant adipose residuum. Can cause congestive heart failure, managed with corticosteroids or embolization during involution. Leaves atrophic skin/subcutaneous tissue; reconstruction with autologous grafts or acellular dermis may be needed. * Noninvoluting Congenital Hemangioma (NICH): Does not regress; remains unchanged with persistent fast-flow. Rarely problematic in infancy. Resection may be indicated to improve appearance if surgical scar is less noticeable.
Kaposiform Hemangioendothelioma (KHE)A rare, locally aggressive vascular neoplasm that does not metastasize. Half are present at birth, others develop in infancy/childhood. * Clinical Features: Equal sex distribution, solitary, affects head/neck (40%), trunk (30%), extremity (30%). Often >5 cm, flat, reddish-purple, edematous. Causes deformity and pain. Over half develop Kasabach–Merritt phenomenon (KMP), characterized by thrombocytopenia (<25,000/mm³), petechiae, and bleeding. KHE does not show rapid postnatal growth but can expand with KMP. Partially regresses after two years, but usually persists long-term, causing chronic pain and stiffness. Shares features with tufted angioma. * Diagnosis: History, physical, MRI (poorly defined margins, small vessels, invasion, T2-hyperintensity, postgadolinium enhancement). Histologically: infiltrating sheets/nodules of endothelial cells, hemosiderin-filled slit-like vascular spaces. * Management: Most lesions are extensive, beyond resection limits. Patients with KMP need systemic treatment to prevent life-threatening complications. Asymptomatic tumors are managed pharmacologically to minimize fibrosis, pain, and stiffness. * Vincristine: First-line therapy with a 90% response rate. Platelet transfusions are not effective for KMP as platelets are trapped in the tumor and can worsen swelling; avoid unless active bleeding is present or surgery is planned. * Other Drugs: KHE responds less well to interferon (50%) or corticosteroid (10%).
Pyogenic Granuloma (PG)Misleadingly named, it is neither "pyogenic" nor "granulomatous"; pathologists sometimes call it lobular capillary hemangioma. * Clinical Features: Solitary, red papule rapidly growing on a stalk. Average diameter 6.5 mm; mean onset age 6.7 years. Male-to-female ratio 2:1. Commonly complicated by bleeding (64%) and ulceration (36%). Primarily involves skin (88%), also mucous membranes (11%). Distributed on head/neck (62%), trunk (19%), upper extremity (13%), lower extremity (5%). Rarely heals spontaneously. * Management: Requires intervention due to ulceration and bleeding. Full-thickness excision is most definitive as superficial modalities (curettage, shave excision, laser) have a 43.5% recurrence rate because the lesion extends into the reticular dermis.
Vascular Malformations: Development and Types
Vascular malformations are structural abnormalities present at birth, though often not apparent until later. They are classified by the predominant vessel type and flow characteristics (slow-flow or fast-flow).
Capillary Malformation (CM): "Port-Wine Stain"The modern term for what was antiquatedly called a "port-wine stain." * Pathogenesis: Not fully understood. The 19th-century "neurovegetative theory" suggested a primary embryonic defect in the autonomic nervous system, supported by geographic/dermatomal patterns (trigeminal nerve branches) and occasional hyperhidrosis. Neuroectoderm contributes to vascular walls. Decreased perivascular neural density in CMs and abnormal leptomeningeal innervation in Sturge-Weber syndrome also support this hypothesis. Cutaneous flush may be due to inability of vessels to constrict due to diminished sympathetic innervation. * Clinical Features: Occur anywhere, localized or extensive. Rarely multiple/generalized (e.g., Sturge–Weber syndrome). Must not be confused with nevus flammeus neonatorum ("angel kiss" or "stork bite"), which typically fades by 2 years. CMs have equal gender distribution, birth prevalence 0.3%. Discoloration usually evident at birth, but can be hidden by neonatal erythema. Often darkens and thickens with age, sometimes with raised fibrovascular cobblestoning. * Location: Facial CMs often dermatomal (45% restricted to trigeminal dermatomes), but 55% overlap sensory dermatomes or cross midline. Mucous membranes often involved. * Complications: Pyogenic granuloma, ulceration, bleeding. Can lead to soft-tissue and skeletal overgrowth below the stain (lip, cheek, forehead hypertrophy; maxilla/mandible enlargement causing occlusal cant). Extensive CM in an extremity can cause increased circumference and limb length discrepancy. Trunk/extremity CMs usually don't show textural/color changes of facial CMs. * Associated Developmental Defects: Occipital CM with hair tuft can overlie encephalocele or ectopic meninges. Posterior thorax CM can signify spinal cord AVM (Cobb syndrome). Cervical/lumbosacral spine CM is a red flag for occult spinal dysraphism, lipomeningocele, tethered spinal cord, diastematomyelia. * Management: * Pulse-Dye Laser Therapy: First-line for CMs, especially facial ones, early in childhood. Superior lightening and reduced risk of darkening/hypertrophy when treated young. Multiple treatments (6 weeks apart) often required. Head/neck respond better than extremities. Smaller lesions and younger age yield better outcomes. 15% achieve >90% lightening; 65% improve 50-90%. Less improvement in Asian patients; higher complication rate (pigmentary changes, hypertrophic scarring) in darker skin. CM often re-darkens over time. * Overgrowth Management: Most patients do not require contouring (e.g., labial hypertrophy) until adolescence or adulthood. Fibrovascular hypertrophy needs adult intervention. Malocclusion corrected by orthodontics or orthognathic procedure after skeletal maturity. Contour burring for facial asymmetry (zygoma, maxilla, mandible). Suction-assisted lipectomy for trunk/extremity soft tissue overgrowth. Excision for small fibrovascular nodules or pyogenic granulomas. Wide resection and reconstruction (linear closure, skin grafts, local flaps) for severe thickening/cobblestoning.
Cutis Marmorata Telangiectatica Congenita (CMTC)Manifests as congenital cutaneous marbling, even at normal temperatures, becoming more pronounced with cold or crying. * Clinical Features: Involved skin is depressed in a serpiginous reticulated pattern, deep purple color. Differential diagnosis: cutis marmorata (transient mottling) and reticular hemangioma. CMTC occurs sporadically, equal gender distribution. Can cause ulceration, localized, segmental, or generalized. Most frequently trunk/extremities, typically unilateral (65%) and lower extremity (69%). Affected extremity often hypoplastic. Most improve during first year and into adolescence. Atrophy, pigmentation, ectasia of superficial veins often persist. May be associated with hypoplasia of iliac/femoral veins. * Macrocephaly-Capillary Malformation (M-CM): A distinct condition, not CMTC. Vascular lesions are patchy, reticular CM (not CMTC), commonly on nose/philtrum, trunk/extremities. Unlike CMTC, M-CM lesions don't ulcerate or fade. Lower limb often hypertrophied. High risk for neurologic abnormalities: developmental delay, mental retardation, megalencephaly, hydrocephalus.
Lymphatic Malformation (LM)Result from errors in the development of the lymphatic system. * Pathogenesis: The lymphatic system develops from the 6th week of embryonic life from lymph sacs. Theories suggest aberrant collections of fluid-filled spaces result from sacs or channels pinching off from the main system, or abnormal budding with lost connection to central channels. Molecular basis is in its infancy; VEGFR3 is restricted to lymphatic endothelium. Mutations in VEGFR3, FOXC2, SOX18, CCBE1 are linked to hereditary lymphedema. * Clinical Features: Characterized by channel size: microcystic, macrocystic, or combined. Macrocystic lesions are large enough for needle puncture. Lymphatic-venous malformation (LVM) can occur due to shared embryological origin. Usually noted at birth or within first 2 years, sometimes later. Prenatal ultrasonography can detect large lesions in 2nd trimester (differentiated from "posterior nuchal translucency" or "cystic hygroma" which have poor prognosis and aneuploidy). * Location: Most common on head/neck, also axilla, chest, perineum. Soft, compressible lesions. Overlying skin can be normal, bluish, or studded with pink-red vesicles. * Complications: Deformity, psychosocial issues (especially head/neck). Leading complications: * Bleeding: Intralesional bleeding in up to 35%, causing discoloration, pain, swelling. * Infection: Complicates up to 70%, can rapidly progress to sepsis. * Obstruction: Swelling (due to bleeding, infection, systemic illness) can obstruct vital structures. Two-thirds of cervicofacial LM infants require tracheostomy. * Bony Overgrowth: Mandible most commonly involved, leading to open bite and prognathism. * Other: Thoracic/abdominal LM can cause chylous effusions. Periorbital LM causes permanent vision reduction (40%), blindness (7%). Generalized LM presents with multifocal/osteolytic bony lesions, splenic involvement, effusions, or "lymphangiectasia" of the bowel with protein-losing enteropathy (Gorham–Stout syndrome, disappearing bone disease). * Diagnosis: 90% by history and physical. Small, superficial lesions need no further evaluation. Large/deep LMs assessed by MRI to confirm, define extent, plan treatment. LM is hyperintense on T2-weighted sequences, no diffuse enhancement. US for macrocystic LM shows anechoic cysts with septations; microcystic LM appears as ill-defined echogenic masses. Histological confirmation rarely needed; shows abnormally walled vascular spaces with lymphocytes; D2-40 and LYVE-1 positive. * Management: Benign lesion, intervention not mandatory. Small/asymptomatic lesions observed. Infected LM often requires intravenous antimicrobial therapy. * Sclerotherapy: First-line for large/problematic macrocystic/combined LM. Cysts aspirated, then inflammatory substance injected to scar cyst walls. Doxycycline is preferred (83% reduction, <5% ulceration); STS is second-line. Ethanol is effective but has highest complication rate and should be avoided near nerves. OK-432 is not widely available. Common complication is cutaneous ulceration (<5%). Ethanol has systemic toxicity (CNS depression, pulmonary hypertension, hemolysis, thromboembolism, arrhythmias). LM often re-expands; patients need repeated sclerotherapy. If macrocysts no longer present, resection is next option. * Resection: Can cause significant morbidity (blood loss, iatrogenic injury, deformity). Usually subtotal, recurrence common (35-64%). Reserved for symptomatic microcystic LM (bleeding, infection, distortion, deformity), symptomatic macrocystic/combined LM no longer manageable by sclerotherapy, or small, well-localized LMs for complete excision. Staged resection for diffuse malformations. Subtotal excision for problematic areas (bleeding vesicles, hypertrophied lip). Macrogossia may require reduction. Bony overgrowth improved by contouring, malocclusion by orthognathic correction. Bleeding/leaking vesicles controlled by localized resection; large areas by sclerotherapy, CO2 laser, or wide resection with skin graft. Radiofrequency ablation for oral microcystic vesicles. LM can expand after any intervention, requiring additional treatments.
Venous Malformation (VM)Result from an error in vascular morphogenesis. * Pathogenesis: Composed of thin-walled, dilated, sponge-like channels of variable size. Normal endothelial lining, but abnormal smooth muscle architecture (decreased cells, clumped rather than concentric). This mural abnormality likely causes gradual expansion. Intralesional clotting (phleboliths) and fibrovascular ingrowth are common. Molecular causes known: 50% of sporadic VM have somatic mutation in endothelial receptor TIE2. Multifocal familial lesions (10%). * Glomuvenous Malformation (GVM): Autosomal dominant with abnormal smooth muscle-like glomus cells along ectatic veins, due to loss-of-function mutation in glomulin gene. * Cutaneomucosal Venous Malformation (CMVM): Autosomal dominant, gain-of-function mutation in TIE2 receptor. * Cerebral Cavernous Malformation (CCM): Familial disorder with VM involving brain/spinal cord, caused by mutations in CCM1/(KRIT1), CCM2, CCM3 genes. * Clinical Features: Blue, soft, compressible; phleboliths often palpable. Range from small, localized to diffuse, involving multiple tissue planes and internal organs. Typically sporadic (90%), solitary. * Sporadic VM: >5 cm (56%), single (99%), head/neck (47%), extremities (40%), trunk (13%). Almost all involve skin/mucosa/subcutaneous tissue; 50% affect deeper structures (muscle, bone, joints, viscera). * GVM: Typically multiple (70%), small (<5 cm, two-thirds), skin/subcutaneous tissue. Extremities (76%), trunk (14%), head/neck (10%). More painful than typical VM. * CMVM: Multifocal mucocutaneous lesions, less common than GVM. Small (76% <5 cm), multiple (73%), head/neck (50%, typically tongue/buccal mucosa), extremity (37%), trunk (13%). * CCM: Familial, brain/spinal cord VM, hyperkeratotic skin lesions. Risk for new intracranial lesions and hemorrhage. * Blue Rubber Bleb Nevus Syndrome (BRBNS): Rare, multiple small (<2 cm) VMs involving skin, soft tissue, GI tract. Morbidity from GI bleeding requiring chronic transfusions. * Diffuse Phlebectasia of Bockenheimer: Extensive extremity VM involving skin, subcutaneous tissue, muscle, bone. * Sinus Pericranii: Venous anomaly of scalp/face with transcalvarial communication to dural sinus. * Verrucous Hemangioma (VH): Low-flow vascular malformation, clinically similar to hyperkeratotic VM. 2-8 cm, extremity (91%) or trunk (9%). Involves skin/subcutis, becomes hyperkeratotic, frequently bleeds. * Maffucci Syndrome: Coexistence of cutaneous VMs with bony exostoses and enchondromas. Osseous lesions appear first, recurrent fractures common. VMs on distal extremities. Malignant transformation (chondrosarcoma) in 20-30%. * Complications: Pain, swelling, psychosocial issues. Head/neck VM: mucosal bleeding, progressive distortion (airway/orbital compromise). Extremity VM: leg-length discrepancy, hypoplasia, pathologic fracture, hemarthrosis, degenerative arthritis. Muscle VM: fibrosis, pain, disability. Large VM in deep venous system: thrombosis, pulmonary embolism. GI VM: bleeding, chronic anemia. Stagnation in large VM: localized intravascular coagulopathy (LIC), painful phlebothromboses. LIC can become disseminated intravascular coagulopathy (DIC) after trauma/intervention. * Diagnosis: >90% by history and physical. Dependent positioning confirms diagnosis. Small, superficial VM need no further workup. Large/deep lesions assessed by MRI (hyperintense on T2, enhances with contrast, phleboliths as signal-voids, more likely to involve muscle). US for localized lesions (compressible, anechoic-hypoechoic channels, hyperechoic phleboliths). CT for osseous VM. Histological diagnosis rarely needed. * Management: * Conservative: Custom-fitted compression garments for extensive extremity VM to reduce blood stagnation, minimize expansion, LIC, phlebolith formation, pain. Prophylactic daily aspirin for recurrent pain from phlebothrombosis. LMWH for patients with significant LIC at risk for DIC. Long-term anticoagulation or vena caval filter for serious thrombotic events. * Sclerotherapy: First-line treatment for symptomatic VMs (pain, deformity, obstruction, GI bleeding). Safer and more effective than resection. Good-excellent results in 75-90% (size reduction, symptom alleviation). Repeated until symptoms alleviate or no injectable spaces. Lesion remains after treatment; may re-expand. Preferred sclerosants: sodium tetradecyl sulfate (STS) and ethanol (more effective but higher complication rate). Managed under general anesthesia with US/fluoroscopic imaging. Common local complication: cutaneous ulceration (<5%). Extravasation into muscle causes atrophy/contracture. Compartment compression for extremity VM. Systemic adverse events (hemolysis, hemoglobinuria, DIC) more common with large lesions. LMWH given for low fibrinogen, held perioperatively. * Resection: Rarely primary treatment (difficult to remove entirely, high recurrence, greater blood loss/injury). Considered for small, well-localized lesions or persistent mass/deformity after sclerotherapy. Weigh postoperative scar/deformity against preoperative appearance. Subtotal resection for problematic areas (e.g., labial hypertrophy) to avoid worse deformity from "complete" excision. Almost all VMs should have sclerotherapy prior to surgery to reduce blood loss, injury, and recurrence, and facilitate dissection. GVM (small, less amenable to sclerotherapy) may have resection as first-line for painful lesions. Nd:YAG photocoagulation as adjuvant for airway lesions. GI VM with chronic bleeding managed by resection. Solitary lesions by endoscopic banding/sclerotherapy. Multifocal lesions of BRBNS require removing as many lesions as possible through multiple enterotomies. Diffuse problematic colorectal VM may need colectomy.
Arteriovenous Malformation (AVM)Result from an error of vascular development between the 4th and 6th weeks of gestation. * Pathogenesis: Failure of arteriovenous channels in primitive retiform plexus to regress. Absent capillary bed causes direct shunting of blood from arterial to venous circulation through a fistula or nidus. AVM is 20 times more common in the CNS where apoptosis is rare. Genetic abnormalities cause familial AVMs (e.g., Hereditary Hemorrhagic Telangiectasia (HHT) from endoglin and activin receptor-like kinase 1 mutations; Capillary Malformation-Arteriovenous Malformation (CM-AVM) from RASA1 mutation). AVM enlarges due to increased blood flow, collateralization, vessel dilatation (especially venous ectasia), and thickening of adjacent arteries/veins. Latent shunts may open, stimulating hypertrophy. Aneurysms can increase size. Angiogenesis/vasculogenesis may be involved, or secondary to ischemia. Increased circulating hormones in adolescence (two-fold progression risk). * Clinical Features: Most common site: head/neck, then limbs, trunk, viscera. Present at birth, but may not be evident until childhood. Early lesions are pink-red cutaneous stains without thrill/bruit, often mistaken for CM or IH. Arteriovenous shunting reduces capillary oxygen, causing ischemia. Risk for pain, ulceration, bleeding. Can cause disfigurement, tissue destruction, obstruction of vital structures. High-pressure shunting can lead to venous hemorrhage; ruptured arteries can form aneurysms. Arterial bleeding most commonly at skin/mucosal surfaces. Can cause high-output cardiac failure. Expansion is primary cause of morbidity. * Schobinger Staging System: Classifies AVM progression: * Stage I (Quiescence): Warm, pink-blue, shunting on Doppler. * Stage II (Expansion): Enlargement, pulsation, thrill, bruit, tortuous veins. * Stage III (Destruction): Dystrophic skin changes, ulceration, bleeding, pain. * Stage IV (Decompensation): Cardiac failure. * Diagnosis: History, physical. Hand-held Doppler reveals fast-flow. US with color Doppler confirms diagnosis. MRI with contrast and fat suppression, T2-weighted sequences needed to confirm, determine extent, plan treatment (shows dilated feeding arteries/draining veins, enhancement, flow-voids). Angiography (tortuous, dilated arteries, shunting, dilated draining veins, nidus) primarily before embolization or planned resection. CT if bone involved. Histopathological diagnosis rarely necessary (risk of bleeding/expansion). * Management: Cure is rare as AVM is often diffuse. Goal: control malformation, alleviate symptoms (bleeding, pain, ulceration), preserve vital functions (vision, mastication), improve deformity. Resection offers best chance for long-term control, but re-expansion rate is high. Almost all AVMs re-expand after embolization (used to reduce blood loss during resection or for palliation of unresectable lesions). Asymptomatic AVM observed unless completely removed with minimal morbidity; incomplete intervention can stimulate enlargement. Intervention individualized by size, location, patient age, Schobinger stage. Resection of asymptomatic Stage I AVM offers best chance for "cure," but consider deformity from resection/reconstruction. Stage III and IV AVMs require intervention for pain, bleeding, ulceration, or cardiac failure. * Embolization: Delivery of inert substance (liquid: n-butyl cyanoacrylate (n-BCA), Onyx; solid: polyvinyl alcohol particles (PVA), coils) into nidus to occlude blood flow. Reduces shunting, shrinks lesion, diminishes symptoms. Used preoperatively or as monotherapy. Almost all lesions re-expand. Stage I AVM has lower recurrence. Occurs within first year, 98% re-expand within 5 years. Can palliate. Embolic material delivered to nidus, not proximal arterial feeding vessels (causes collateralization, blocks future embolization). Temporary substances for preoperative embolization; permanent liquid agents for primary treatment. Most frequent complication: ulceration. * Resection: Lower recurrence than embolization alone. Considered for well-localized lesions or to correct deformity (bleeding/ulcerated areas, labial hypertrophy). Wide extirpation of large, diffuse AVM exercised with caution (rare cure, high recurrence, worse deformity, significant blood loss/injury). Preoperative embolization facilitates procedure by reducing size, blood loss, creating scar tissue. Excision 24-72 hours post-embolization. Resection margins determined by wound edge bleeding. Local skin flaps, regional flap transfer for ulcerated areas (skin grafting has high failure). Free-flap reconstruction permits wide resection but doesn't improve long-term control. Most AVMs recur after resection (within first year, 86.6% within 5 years), but many patients remain asymptomatic.
Capillary Malformation-Arteriovenous Malformation (CM-AVM)An autosomal dominant condition from a loss-of-function mutation in the RASA1 gene (prevalence 1 in 100,000 Caucasians). * Clinical Features: Atypical CMs (small, multifocal, round, pinkish-red, often with pale halo, 50%). 30% also have an AVM: Parkes Weber syndrome (PWS) (12%), extracerebral AVM (11%), or intracerebral AVM (7%). A patient with multiple CMs, especially with family history, should be evaluated for AVM. Brain MRI considered due to 7% risk of intracranial fast-flow lesion. Extracranial AVMs not found to involve viscera. CM rarely problematic, but associated AVMs can cause major morbidity.
Flashcards
1 / 51
Tap to flip · Swipe to navigate
Eponymous Vascular Anomalies with Overgrowth
These syndromes combine specific vascular anomalies with characteristic overgrowth patterns.
Sturge–Weber Syndrome (SWS)A sporadic neurocutaneous disorder (1 in 50,000 live births). * Cardinal Features: Capillary malformation (CM) in upper trigeminal neural distribution, ocular abnormalities (glaucoma, choroidal vascular anomalies), and leptomeningeal vascular malformation. Also common: soft tissue/bony overgrowth (60-83%). Frequency similar for glaucoma (65-77%) and neurological sequelae (87-93%). * Diagnosis: Upper facial CM, as well as V1-V2 distribution, raises suspicion. Maxillary or mandibular involvement alone has low risk. Ophthalmic exam every 6 months until age 2, then yearly. MRI best demonstrates pial vascular enhancement. Anomalous choroidal vascularity leads to retinal detachment, glaucoma, blindness. * Associated Features: Extra-craniofacial CMs (29%) and extremity hypertrophy (14%) are frequent. SWS patients do not have combined venous, lymphatic, or arterial anomalies in an extremity, unlike Klippel-Trénaunay or Parkes Weber syndromes, though simple diffuse venous varicosities can occur.
Klippel–Trénaunay Syndrome (KTS)Denotes a slow-flow, capillary-lymphatic-venous malformation (CLVM) of an extremity, with soft tissue and/or skeletal overgrowth. Often incorrectly called "Klippel–Trénaunay–Weber." * Clinical Features: Tremendous variability. Affects lower extremity (95%), upper extremity (5%), least commonly trunk. Contralateral foot/hand enlargement possible, sometimes with macrodactyly without CM. 10% have hypoplastic limb. Pelvic involvement common with lower extremity CLVM, usually asymptomatic (hematuria, bladder outlet obstruction, cystitis, hematochezia can occur). Upper extremity/truncal CLVM can involve posterior mediastinum/retropleural space. CM in geographic pattern over lateral extremity, buttock, thorax (macular in neonate, later studded with hemolymphatic vesicles). Venous component: abnormal drainage. Lymphatic abnormalities: macrocystic in pelvis/thighs, microcystic in abdominal wall/buttock/distal limb. * Diagnosis: MRI confirms diagnosis, determines extent. Large embryonal vein (marginal vein of Servelle) often in lateral calf/thigh, communicates with deep venous system. * Complications: Thrombophlebitis (20-45%), pulmonary embolism (4-24%). Not at increased risk for Wilms tumor. * Management: Annual radiographic surveillance of leg length by plain radiography. Shoe-lift for >1.5 cm discrepancy. Epiphysiodesis of distal femoral growth plate typically around 11 years. Foot enlargement may need amputation. VM component: conservative management with compressive stockings for insufficiency, aspirin to minimize phlebothrombosis. Sclerotherapy for symptomatic varicose veins or focal macrocystic lymphatic malformation/cutaneous vesicles. Excision/grafting for diffuse bleeding/oozing vesicles. Staged contour resection for circumferential overgrowth.
Parkes Weber Syndrome (PWS)A diffuse AVM in an overgrown extremity with an overlying CM. * Clinical Features: Involves lower extremity twice as often as upper. Microshunting in muscle. Evident at birth with symmetric enlargement and pink staining of involved limb. Cutaneous stain tends to be confluent, warmer than banal CM. Diagnosis confirmed by bruit or thrill. * Diagnosis: MRI evaluates extent. Overgrowth is subcutaneous, muscular, bony with diffuse microfistulas. Angiography demonstrates discrete arteriovenous shunts. * Management: Predicated on symptoms. Rare infants with high-output congestive heart failure need emergent embolization with permanent occlusive agents, often repeated. Children observed annually for axial overgrowth, cutaneous problems. Embolization for pain or cutaneous ischemic changes. Amputation occasionally necessary.
PTEN Hamartoma-Tumor Syndrome (PHTS)Also known as Cowden syndrome or Bannayan–Riley–Ruvalcaba syndrome. Autosomal dominant, caused by PTEN mutations (a tumor suppressor gene). * Clinical Features: Males and females equally affected. About 54% have a unique fast-flow vascular anomaly with arteriovenous shunting (PTEN-associated vascular anomaly). Multiple lesions (57%), 85% intramuscular. All patients have macrocephaly (>97th percentile), males have penile freckling. Associated with mental retardation/autism (19%), thyroid lesions (31%), GI polyps (30%). * Diagnosis: Suspicion raised by MRI/angiography of AVM. Unlike typical AVM, these lesions may be multifocal and associated with ectopic adipose tissue, segmental dilation of draining veins. Physical exam for macrocephaly and penile freckling. Biopsy aids diagnosis (skeletal muscle infiltration with adipose, fibrous bands, lymphoid aggregates; tortuous arteries with transmural muscular hyperplasia; abnormal veins). Genetic testing is confirmative (though 9% of clinical PHTS families lack germline mutation). If physical exam consistent, molecular testing is necessary due to association with multiple benign and malignant tumors requiring surveillance. * Management: Patients monitored for tumors, especially endocrine/GI malignancies. Counselled about gene transmission risk. Symptomatic lesions managed similarly to nonsyndromic AVM, with embolization or resection. Recurrence rate after intervention may be even higher than for nonsyndromic AVM.
CLOVES Syndrome
C ongenital L ipomatosis O vergrowth, V ascular malformations, E pidermal nevi, and S coliosis (CLOVES) is a newly described overgrowth syndrome, previously confused with Proteus syndrome (but CLOVES lacks skeletal involvement and soft-tissue component is not progressive). * Clinical Features: All patients have a truncal lipomatous mass, a slow-flow vascular malformation (most commonly a CM overlying the lipomatous mass), and hand/foot anomalies (increased width, macrodactyly, first web-space sandal gap). Patients may also have AVM (28%), neurological impairment (50%), or scoliosis (33%). * Management: Resection for lipomatous lesions, but recurrence rate is high.
Conclusion on Vascular Anomalies
For many centuries, vascular anomalies were poorly understood, often leading to misdiagnosis and ineffective treatment. The modern biological classification has provided a common language for specialists, enabling better communication, diagnosis, and management. Dedicated vascular anomaly teams, composed of various medical and surgical disciplines, are crucial in providing comprehensive care and advancing research in this exciting field.
Frequently Asked Questions about Vascular Anomalies
What is the main difference between vascular tumors and vascular malformations?
The main difference lies in their cellular behavior. Vascular tumors are characterized by active proliferation of endothelial cells (cells lining blood vessels), meaning they grow rapidly. Vascular malformations, in contrast, are structural defects present from birth with quiescent (non-proliferating) endothelial cells, meaning they are errors in development rather than active growths.
How are Infantile Hemangiomas (IH) typically diagnosed and treated?IH are usually diagnosed by history and physical examination, often confirmed by hand-held Doppler or ultrasonography. Most small, localized IHs are simply observed as they naturally regress. Problematic or complicated IHs can be treated with systemic pharmacotherapy like oral prednisolone or propranolol, or in specific cases, with intralesional corticosteroids or surgical resection.
What are the challenges in managing Kaposiform Hemangioendothelioma (KHE)?KHE is a rare, locally aggressive tumor often complicated by Kasabach–Merritt phenomenon (KMP), a life-threatening coagulopathy. Management is challenging because most lesions are extensive and cannot be fully resected. Systemic treatment with vincristine is the first-line therapy, focusing on controlling KMP and minimizing long-term pain and stiffness.
How are Capillary Malformations (CM) managed, especially on the face?
Facial Capillary Malformations (CMs), often called "port-wine stains," are best treated with pulsed-dye laser therapy early in childhood. This intervention can improve lightening of the lesion and reduce the risk of darkening and hypertrophy over time. Multiple treatments are often required, and while outcomes vary, early intervention is generally preferred.